Riskpilot← Back to searchSign inGet full accessPandalyze AB
ABActiveOrg 5591004881Bataljonsgatan 31General medical practice activities · NACE 8621Est. 20170 employees
Revenue 2025
SEK 0
EBITDA margin
—
-173% vs 2024
Equity ratio
100.0%
Financial strength
Net profit 2025
SEK -20K
-187% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -20K | -173% |
| Net profit | SEK -20K | -187% |
| Total assets | SEK 113K | -29% |
| Equity | SEK 113K | -19% |
| Employees | 0 | — |
Legal name
Pandalyze AB
Org number
5591004881
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
13 februari 2017
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget skall vara verksamt inom branschen hälsa och sjukvård och bedriva medicinsk och radiologisk diagnostik, behandling och konsultation i öppenvård, slutenvård och via internet. Aktiebolaget skall vidare vara verksamt inom friskvård, idrottsmedicin, höghöjdsmedicin, navalmedicin, terapeutiskt arbete, personlig utveckling, skönhetsvård, foto/konst, författarskap och språktjänster samt bedriva detaljhandel inom ovanstående områden.
Address
Bataljonsgatan 31
Email
angie.dongliu@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 121 | 43 | −0 | −0 | 0 |
| Staff expenses | — | −6 | −0 | — | — |
| EBITDA | 94 | 34 | −5 | −7 | −20 |
| Depreciation & amort. | −0 | — | — | — | −0 |
| EBIT | 94 | 34 | −5 | −7 | −20 |
| Net financials | — | — | −0 | 0 | — |
| Profit before tax | 94 | 34 | −5 | −7 | −20 |
| Tax | −19 | −7 | — | — | −0 |
| Net profit | 75 | 27 | −5 | −7 | −20 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 157 | 168 | 165 | 159 | 113 |
| Equity | 125 | 151 | 146 | 139 | 113 |
| Long-term debt | 0 | — | — | — | 0 |
| Short-term debt | 33 | 17 | 19 | 20 | 0 |
| Total debt | 33 | 17 | 19 | 20 | — |
EBITDA margin
-2000000.0%
This company
15.8%
Market median
-12658328% vs market
20212025
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20212025
Return on equity
-17.7%
This company
18.4%
Market median
-196% vs market
20212025
Net profit margin
-2000000.0%
This company
8.1%
Market median
-24691458% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
DL | Deputy Board Member | 2022 |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Pandalyze AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Angie Liu | Board of Directors | 0 companies |
| Meiying Dong | Deputy Board Member | 0 companies |
| Dake Liu | Deputy Board Member | 0 companies |